# Assessing Clinical Outcomes in Alzheimer's Disease Agitation

> **NCT04797715** · PHASE3 · COMPLETED · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 178 (actual)

## Conditions studied

- Agitation in Patients With Dementia of the Alzheimer's Type
- Alzheimer Disease
- Agitation,Psychomotor

## Interventions

- **DRUG:** AXS-05
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04797715
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-31
- **Primary completion:** 2022-11-21
- **Final completion:** 2022-11-21
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797715, "Assessing Clinical Outcomes in Alzheimer's Disease Agitation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04797715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*